セフェピム
安全性情報
- リスクと安全性に関する声明
- 危険有害性情報のコード(GHS)
| 絵表示（GHS） |
|
| 注意喚起語 |
警告 |
| 危険有害性情報 |
| コード |
危険有害性情報 |
危険有害性クラス |
区分 |
注意喚起語 |
シンボル |
P コード |
| H302 |
飲み込むと有害 |
急性毒性、経口 |
4 |
警告 |
|
P264, P270, P301+P312, P330, P501 |
|
| 注意書き |
| P280 |
保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。 |
| P305+P351+P338 |
眼に入った場合：水で数分間注意深く洗うこと。次にコ ンタクトレンズを着用していて容易に外せる場合は外す こと。その後も洗浄を続けること。 |
|
セフェピム 価格
| メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
セフェピム 化学特性,用途語,生産方法
効能
抗生物質, 細胞壁合成阻害薬
説明
Cefepime is a new fourth-generation parenteral cephalosporine antibiotic launched in
1993 in Sweden and France. Cefepime has broad spectrum antimicrobial activity against
Staphylococcus, Strepfococcus, Pseudomonas, and the Enterobacteriaceae, including many
bacterial isolates that are resistant to commonly used ceftazidime and cefotaxime. Its
efficacy has been demonstrated in the treatment of lower respiratory tract infections
especially pneumonia, intra-abdominal and urinary tract infections, skin and soft tissue
infections, chronic osteomyelitis and in prophylaxis of biliary tract and prostate infections. It
is well tolerated by patients and is reported to exhibit no significant drug interactions.
化学的特性
colorless Powder
使用
Cefepime is used for bacterial infections caused by microorganisms that are sensitive to
drugs in septicemia, bacteriemia, complicated infections of the upper and lower sections
of the urinary system, pneumonia, pulmonary abscesses, emphysema of the pleura, fever
in patients with neutropenia, and infected skin and soft tissue wounds. Synonyms of this
drug are maxipime, cepim, cepimex, and others.
抗菌性
Its activity against common pathogens is comparable
to that of group 4 cephalosporins, but it is somewhat
more active against Ps. aeruginosa. Like cefpirome it has low
affinity for the molecular class C cephalosporinases of many
Gram-negative rods and is consequently active against
most strains of Citrobacter spp., Enterobacter spp., Serratia spp.
and Ps. aeruginosa that are resistant to cefotaxime and ceftazidime.
It has poor activity against L. monocytogenes and against
anaerobic organisms.
薬物動態学
C
max 2 g intravenous (30-min infusion): c. 160 mg/L end infusion
Plasma half-life: c. 2 h
Volume of distribution: 14–20 L
Plasma protein binding: 10–19%
It is well distributed. Penetration into tissues, including lung,
appears to be similar to that of other aminothiazoyl cephalosporins.
Very low concentrations are achieved in CSF in the
absence of meningeal inflammation. It is secreted in breast
milk.
It is partially metabolized, but 85% of the dose is excreted
unchanged in the urine, achieving a concentration approaching
1 g/L within 4 h of a 1 g intravenous dose. Dosage adjustment
is required in patients with impaired renal function,
but hepatic impairment does not affect the pharmacokinetic
properties.
臨床応用
Cefepime (Maxipime, Axepin) is a parenteral, β-lactamase–resistant cephalosporin that is chemically and microbiologicallysimilar to cefpirome. It also has a broadantibacterial spectrum, with significant activity against bothGram-positive and Gram-negative bacteria, including streptococci,staphylococci, Pseudomonas spp., and theEnterobacteriaceae. It is active against some bacterial isolatesthat are resistant to ceftazidime. The efficacy of cefepimehas been demonstrated in the treatment of urinary tract infections,lower respiratory tract infections, skin and soft tissueinfections, chronic osteomyelitis, and intra-abdominal andbiliary infections. It is excreted in the urine with a half-life of2.1 hours. It is bound minimally to plasma proteins. Cefepimeis also a fourth-generation cephalosporin.
副作用
It is used in the treatment of serious infections, particularly
those in which resistant Gram-negative pathogens are known
or suspected to be involved.
セフェピム 上流と下流の製品情報
原材料
準備製品
セフェピム 生産企業
Global( 185)Suppliers
88040-23-7(セフェピム)キーワード:
- 88040-23-7
- [6R-[(6α，7β(Z)]]-7-[[(2-Amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-y1]methy1]-1-methylpyrrolidinium inner salt
- (6R)-7α-[[(2-Amino-4-thiazolyl)[(Z)-methoxyimino]acetyl]amino]-3-[(1-methylpyrrolidinio)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid ion
- (6R,6β)-7α-[[(2-Amino-4-thiazolyl)[(Z)-methoxyimino]acetyl]amino]-8-oxo-3-[[(1-methylpyrrolidinium)-1-yl]methyl]-5-thia-1-azabicyclo[4.2.0]octa-2-ene-2-carboxylic acidion
- Cefpim
- CFPM
- (6R,7R)-7-{[(2Z)-2-(2-AMINO-1,3-THIAZOL-4-YL)-2-(METHOXYIMINO)ACETYL]AMINO}-3-[(1-METHYL-1-PYRROLIDINIUMYL)METHYL]-8-OXO-5-THIA-1-AZABICYCLO[4.2.0]OCT-2-ENE-2-CARBOXYLATE
- PyrrolidiniuM, 1-[[(6R,7R)-7-[[(2Z)-2-(2-aMino-4-thiazolyl)-2-(MethoxyiMino)acetyl]aMino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]Methyl]-1-Methyl-, inner salt
- Cefepime sodium
- cefepime sterile(L-arginine)_
- CEFEPIME
- [6r-[6alpha,7beta(z)]]-1-[[7-[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-methylpyrrolidinium hydroxide inner salt
- Cefepime Jp
- BMY 28142
- FR 81335
- Pyrrolidinium, 1-[[(6R,7R)-7-[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-methyl-, inner salt
- Pyrrolidinium, 1-[[7-[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-methyl-, inner salt, [6R-[6α,7β(Z)]]-
- Tsefepim
- (6R,7R)-7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-methoxyimino-1-oxoethyl]amino]-3-[(1-methyl-1-pyrrolidin-1-iumyl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
- Cefepime, ＞98%
- Cefepime (CFPM)
- Cefepime (Maxipime)
- Cefepime (free base)
- Cefepime USP/EP/BP
- Cefepime
DISCONTINUED. Please see C242750
- Cefepime impurity
- CEFEPIME ARGININE
- (6R,7R)-7-[(Z)-2-(2-Amino-4-thiazolyl)-2-(methoxyimino)acetamido]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
- セフピム
- (6R,7R)-7-[(Z)-2-(2-アミノ-4-チアゾリル)-2-メトキシイミノアセチルアミノ]-3-(1-メチルピロリジニオメチル)-8-オキソ-5-チア-1-アザビシクロ[4.2.0]オクタ-2-エン-2-カルボキシラート
- (6R,6β)-7α-[[(2-アミノ-4-チアゾリル)[(Z)-メトキシイミノ]アセチル]アミノ]-8-オキソ-3-[[(1-メチルピロリジニウム)-1-イル]メチル]-5-チア-1-アザビシクロ[4.2.0]オクタ-2-エン-2-カルボン酸イオン
- (6R)-7α-[[(2-アミノ-4-チアゾリル)[(Z)-メトキシイミノ]アセチル]アミノ]-3-[(1-メチルピロリジニオ)メチル]-8-オキソ-5-チア-1-アザビシクロ[4.2.0]オクタ-2-エン-2-カルボン酸イオン
- セフェピム
- 1-{[(6R,7R)-7-[(2Z)-2-(2-アミノ-1,3-チアゾール-4-イル)-2-(メトキシイミノ)アセトアミド]-2-カルボキシラト-8-オキソ-5-チア-1-アザビシクロ[4.2.0]オクタ-2-エン-3-イル]メチル}-1-メチルピロリジン-1-イウム
- 1-{[(6R,7R)-7-[(2Z)-2-(2-アミノ-1,3-チアゾール-4-イル)-2-(メトキシイミノ)アセトアミド]-2-カルボキシ-8-オキソ-5-チア-1-アザビシクロ[4.2.0]オクタ-2-エン-3-イル]メチル}-1-メチルピロリジン-1-イウム
- (7R)-7-[(Z)-2-(2-アミノチアゾール-4-イル)-2-(メトキシイミノ)アセチルアミノ]-3-[(1-メチルピロリジニオ)メチル]セファム-3-エン-4-カルボン酸
- 1-メチル-1-[[(6R,7R)-2-カルボキシ-7-[[2-[(Z)-メトキシイミノ]-2-(2-アミノチアゾール-4-イル)アセチル]アミノ]-8-オキソ-5-チア-1-アザビシクロ[4.2.0]オクタン-2-エン]-3-イルメチル]ピロリジニウム
- セファロスポリン類